Printer Friendly

ORTHOFIX INTERNATIONAL N.V. FILES REGISTRATION STATEMENT WITH THE SEC

ORTHOFIX INTERNATIONAL N.V. FILES REGISTRATION STATEMENT WITH THE SEC
 LONDON, March 19 /PRNewswire/ -- Orthofix International N.V. ("Orthofix"), a leading producer of external fixation devices used in fracture treatment, limb lengthening and bone reconstruction, has filed a registration statement with the Securities and Exchange Commission (SEC) in connection with a proposed public offering in the United States of an aggregate of 2,600,000 common shares and a concurrent offering outside the United States of an aggregate of 650,000 common shares. Of the 3,250,000 common shares being offered, 2,079,914 are being sold by Orthofix and 1,170,086 are being sold by certain of its shareholders. It is anticipated that the proposed sale to the public will commence in late April 1992.
 It is currently estimated that the initial public offering price for the common shares will be between $14 and $16 per share. The net proceeds of the offering to Orthofix will primarily be used to acquire licenses, products or companies in the trauma, orthopedic and related medical fields, to fund research and development and for working capital and general corporate purposes.
 Alex. Brown & Sons Inc. and Oppenheimer & Co. Inc. are the lead managers of the U.S. and international offerings.
 A registration statement relating to these securities has been filed with the U.S. SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state.
 No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date. An indication of interest in response to this announcement will involve no obligation or commitment of any kind.
 -0- 3/19/92 R
 /CONTACT: Robert Gaines Cooper, Edgar Wallner or Peter Clarke of Orthofix International N.V., 44-491-579600, or (fax) 44-491-579750/ CO: Orthofix International N.V. ST: IN: HEA MTC SU: OFR


EH-JL -- SD004 -- 9689 03/19/92 12:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:419
Previous Article:REPOSSESSION AUCTION, INC., REPORTS NASDAQ NMS LISTING AND EARNINGS FOR THE YEAR ENDED DEC. 31, 1991
Next Article:TY-D-BOL SPRING CLEANING REPORT: "CONGRESS NEEDS A GOOD SPRING CLEANING"
Topics:


Related Articles
ORTHOFIX ANNOUNCES FIRST QUARTER RESULTS
ORTHOFIX INTERNATIONAL N.V. ANNOUNCES THIRD QUARTER RESULTS
ORTHOFIX AFFILIATE WINS FIRST PATENT INFRINGEMENT CASE ON FOOT PUMP; COMPANY TO INCREASE SHAREHOLDING IN NOVAMEDIX
ORTHOFIX REPORTS SECOND QUARTER RESULTS
Federal Court Rejects EBI/Biomet Challenge to Jury Verdict and Upholds Award of $100 Million to Orthofix
Orthofix Announces Distribution Agreement with Sulzer
Orthofix Enters Distribution Agreement With Sofamor Danek Group
Orthofix Receives FDA Approval to Modify Labeling on Bone Growth Stimulators
Orthofix Performance Nets Payment for American Medical Electronics Shareholders; $500,000 Plus Possible $5.5 Million if EBI Litigation Successful.
Federal Appellate Court Unanimously Affirms Compensatory Award for Orthofix of $48M Plus Interest.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters